Obimal (Otilonium Bromide)

Otilonium bromide, the active ingredient in Obimal, is an antispasmodic (spasmolytic) presented as an oral formulation for oral use. It is used to relieve gastrointestinal smooth‑muscle spasms in conditions such as irritable bowel syndrome, abdominal pain and intestinal colic.

GNH USA supplies Obimal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Obimal, an antispasmodic acting on gastrointestinal smooth muscle, is indicated for several functional bowel disorders.

- Irritable bowel syndrome: reduces abdominal cramping and improves bowel habit regularity. - Abdominal pain: alleviates pain caused by intestinal spasm. - Intestinal colic: eases severe, episodic abdominal discomfort associated with colic.

Adverse reactions may occur with any antispasmodic therapy.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Constipation: slowed intestinal transit. - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Hepatic dysfunction: elevated liver enzymes. - Pancreatitis: abdominal pain with elevated enzymes.

Before initiating therapy, consider the following safety measures.

- Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: evaluate risk versus benefit with a clinician. - Hepatic impairment: use with caution; monitor liver function. - Renal impairment: adjust use if necessary; monitor renal parameters. - Concomitant anticholinergics: may increase antimuscarinic effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Otilonium bromide may interact with other medications; awareness of interaction severity is important.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase systemic exposure. - Other anticholinergic agents: risk of additive antimuscarinic effects.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible additive blood pressure lowering. - Diuretics: monitor electrolyte balance. - Antidepressants with anticholinergic properties: watch for enhanced side effects.